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828 amino acids. 
Function 
PPP1R13L was originally named RAI, an acronym for 
RelA associated inhibitor. It was originally identified 
by yeast two-hybrid screening using RelA as bait. 
PPP1R13L was shown to associate specifically with 
relA and inhibit relA mediated NF-kappaB activated 
transcription when NF-kappaB specific transcription 
was activated by TNF. Yang et al. found no interaction 
with p53. The mRNA expression was examined in 
several tissues and was found to be high in heart, 
placenta, prostate tissues and detectable in lung, 
kidney, pancreas, spleen thymus, ovary, small intesti  
and colon. Bergamaschi et al found that PPP1R13L 
interacts with p53. Antisense RNA or RNAi mediated 
down regulation of PPP1R13L expression and induced 
apoptosis. Increased expression of PPP1R13L lead to 
increased resistance towards cisplatin and UV-induce  
apoptosis. This indicates that RAI inhibits apoptosis. 
Several studies provide evidence that PPP1R13L 
expression is increased in tumor tissue. In a study of 
colorectal adenomas and colorectal cancers, PPP1R13L 
expression was found to be substantially higher in 
lesions than in the normal tissue from the same pati nt. 
PPP1R13L expression has also been found to be 
increased in breast carcinomas and in blood cells in 
patients with acute leukemia. 
In a prospective study of lung cancer among 265 lung 
cancer cases and 272 controls nested within the 
population based 'Diet, Cancer and Health study', 
PPP1R13L expression in mononuclear blood cells 
(isolated by buffy coat) was not associated with risk of 
lung cancer. mRNA levels were found to be 41% 
higher in women than in men. 
Mutations 
Note: Genetic Epidemiology:  
The most frequently studied polymorphism in 
PPP1R13L is PPP1R13L IVS1 A4364G (rs1970764). 
Carriers of the variant allele have been shown to be at 
decreased risk of basal cell carcinoma among younger 
persons (<50 years), breast cancer (<55 years) and lung 
cancer (<56 years). 
The polymorphism is part of a haplotype, which has a 
stronger association with risk of cancer than the 
polymorphism itself. Homozygous carriers of the 
haplotype ERCC1 Asn118AsnA, ASE-1 G-21AG, 
PPP1R13L IVS1 A4364GA have been shown to be at 
increased risk of breast cancer and lung cancer. Thus, 
women who were homozygous carriers of the 
haplotype ERCC1 Asn118AsnA, ASE-1 G-21AG, RAI 
IVS1 A4364GA, had a 9.5-fold higher risk of breast  
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cancer before 55 years of age than women who were 
not homozygous carriers of the haplotype. Older 
women and heterozygous carriers were not at an 
increased risk of breast cancer. Homozygous carriers of 
the haplotype were found to be at 4.9-fold increased 
risk of lung cancer in the age interval 50-55 years. The 
association was stronger among women than among 
men, although the difference was not statistically 
significant. In subsequent study including more cases 
and a larger comparison group, a statistically 
significant difference between genders was found. 
Furthermore, it was found that the haplotype interacts 
with smoking intensity. Thus, among women, who 
were carriers of the haplotype, additional smoking at 
high smoking intensity (>20 cigarettes/day) was 
associated with increased lung cancer risk. This wa
not seen among women who were not homozygous 
carriers of the haplotype or among men. 
The haplotype was not associated with risk of testis 
cancer or with risk of colorectal adenomas or colorectal 
cancer. Furthermore, the haplotype was not associated 
with risk of basal cell carcinoma among older persons 
(>60 years). 
These results indicate that the haplotype may be 
associated with risk of cancer primarily among young 
and middle aged persons and that it may be specific for 
women. 
Implicated in 
General increased cancer risk 
Note: No human disease has been linked to inactivation 
of PPP1R13L. However, polymorphisms in PPP1R13L 
may be associated with increased cancer risk (see 
above). 
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